Cynomolgus GPA Protein (GPA-CM101)
$283.50 – $945.00
KACTUS Biosystems Cynomolgus GPA Protein (GPA-CM101) (catalog No. GPA-CM101) is expressed from HEK293 with His tag at the C-Terminus.It contains Ser20-Glu91.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | GPA-CM101 |
|---|---|
| Product Name | Cynomolgus GPA Protein (GPA-CM101) |
| Supplier Name | KACTUS Biosystems |
| Brand Name | KACTUS Biosystems |
| Species | Cynomolgus |
| Source | HEK293 |
| Accession | A0A2K5WD82 |
| Product Tag | C-His |
| Biotinylated | no |
| Exact Sequence | Ser20-Glu91 |
| Molecular Weight | The protein has a predicted MW of 9 kDa. Due to glycosylation, the protein migrates to 30-45 kDa based on Tris-Bis PAGE result. |
| Form | Lyophilized |
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Endotoxin | Less than 1EU per μg by the LAL method. |
| Shipping | Shipped at ambient temperature. |
| Stability & Storage | '-20 to -80°C for 12 months as supplied from date of receipt.；-20 to -80°C for 3-6 months in unopened state after reconstitution.；2-8°C for 2-7 days after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Note | Products will be shipped from the warehouse in Massachusetts. Promotion is running from time to time. Welcome to send a request for quote to message@sydlabs.com. |
| Order Offline | Syd Labs, Inc. 4 Avenue E, Hopkinton, MA 01748 USA. Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com |
Description
GPA-CM101: Cynomolgus GPA Protein (GPA-CM101)
Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.
Please remember our product information: Cynomolgus GPA Protein (GPA-CM101) catalog number: GPA-CM101 KACTUS Biosystems
Additional information
| Ship from Country | USA |
|---|---|
| Size | 100 ug, 500 ug |
